Company / SG&A Expense
Monopar Therapeutics SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$6.8M
FY2025
5-year range
$1.2M / $6.8M
FY2021-FY2025
Trend
+110.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $912,474 in FY2017 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025.
Increased from $3M to $7M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Monopar Therapeutics's sg&a expense has grown for 5 consecutive years.
- In FY2025, sg&a expense increased 110.5% year-over-year.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.8M | +110.5% |
| FY2024 | $3.2M | +9.7% |
| FY2023 | $2.9M | +25.1% |
| FY2019 | $2.4M | +102.0% |
| FY2018 | $1.2M | +27.8% |
| FY2017 | $912.5K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026